Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 492 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 492 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $38.73, for a total value of $19,055.16. Following the completion of the sale, the chief executive officer now directly owns 660,474 shares of the company’s stock, valued at approximately $25,580,158.02. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Twist Bioscience Stock Down 3.5 %

NASDAQ TWST opened at $36.19 on Friday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -10.71 and a beta of 2.34. The company has a 50 day moving average of $43.80 and a 200-day moving average of $45.10. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.75) EPS. On average, equities research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in shares of Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after acquiring an additional 580 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter valued at approximately $34,000. Van ECK Associates Corp lifted its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the last quarter. Banque Transatlantique SA acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at $43,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience in the 4th quarter valued at $58,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wolfe Research started coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a research note on Friday, March 28th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Finally, Barclays set a $58.00 price objective on Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $54.10.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.